Can robots really transform the pharmacy industry? Walgreens certainly thinks so, as it doubles down on robotic micro-fulfillment centers to reshape its pharmacy operations. These centers, which have been operational since 2021, are now expanding their reach to serve more than 5,000 stores by the end of 2025, up from 4,800 in February. This ambitious move aims to automate up to half of Walgreens’ prescription volume, freeing pharmacists to focus on clinical care and enhancing customer satisfaction.
Walgreens’ investment in automation is a strategic pivot to address several challenges, including staffing shortages and rising competition from online retailers like Amazon. By eliminating routine tasks, the company hopes to create a more attractive work environment for healthcare professionals. The automated centers employ advanced technology, such as robotic arms and conveyor belts, to dispense maintenance prescriptions for chronic diseases like diabetes and high blood pressure. Not only does this minimize excess inventory, but it also saves prescription filling costs by almost 13% year-over-year, as per a report from Becker’s Hospital Review.
The advantages of this automation initiative are already visible. Walgreens has seen around $500 million in savings so far since the launch, based on reduced inventory and operating efficiencies. This year, by further scaling automation, the company anticipates an added $1.1 billion in savings by 2025. These figures are crucial for a company that has witnessed 3.5% same-store sales decline in Q2 2023. Automation can add 1-2% to EBITDA margins by 2025, an eventful change for the sector that has been touting thin profit margins, as a report by AInvest.
Aside from cost savings, genuine disruption is more likely to be role displacement for pharmacists. By simplifying routine work, Walgreens believes it can transform its 100,000+ employees into clinical care givers. Robot locations within current stores have provided 40% more vaccinations and utilized 25% more patient time. It’s all within a larger trend in healthcare: the expanding scope of practice among pharmacists now encompasses treating conditions like asthma and COPD, and adding new revenue streams through value-based care agreements.
However, issues exist. There have been reports of late deliveries and fills short of prescriptions, although Walgreens blames them on growing pains. Smaller-sized prescription fill vials and more sophisticated training programs will be working to fix the problems. The firm is also investing in other digital innovations, including a 30-minute pickup promise on curbside and drive-thru orders and 24-hour delivery at almost 400 locations, according to a report by PYMNTS.
Walgreens’ automation strategy is an 8x bet, i.e., high risk or high reward. The estimated cost saving of $1.6 billion by 2025 and 50% decrease in clerical labor to dispense prescriptions could reduce costs and release pharmacists to create top-line growth through clinical services. If successful, the model can drive EBITDA margins to 8% (from 6.2% in 2022) and be worth improved stock valuation. Execution is important. Its rivals such as CVS are investing in automation too, and Amazon’s home delivery of prescription medication is a threat. Walgreens needs to ensure its robot centers are not clogged up, are accurate, and utilize the pharmacists’ ability to the maximum.
The big-box bet on robots is not about keeping pace it’s about being reborn as a health care company at the moment when clinical value and convenience are the standards of success. The test is that it might succeed, but Walgreens will need to demonstrate that it can do so extremely, extremely well against a tight deadline in a high-stakes game of catch-up.
